48 results on '"Kim Won Seog"'
Search Results
2. TET2 and LILRB1 mutations are frequent in Epstein–Barr virus‐positive diffuse large B‐cell lymphoma especially in elderly patients
3. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
4. A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort
5. Promising clinical efficacy and acceptable safety profile of sequential P‐GEMOX and radiotherapy for localized ENKTL
6. Prognostic value of single‐nucleotide polymorphisms for extranodal natural killer/T‐cell lymphoma: the identification of risk factors in the molecular era
7. Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis
8. Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 + cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation
9. Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
10. Global Collaborations
11. Natural Killer/T‐cell Lymphomas
12. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
13. Impact of fear of cancer recurrence on survival among lymphoma patients
14. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
15. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
16. Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T‐cell lymphoma
17. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy
18. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy
19. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
20. Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
21. Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma
22. Systemic Epstein–Barr virus‐negative mature natural killer‐cell lymphoma with cutaneous and visceral involvement
23. Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T‐cell lymphoma, nasal type
24. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
25. Integrated copy number and gene expression profiling analysis of epstein–barr virus‐positive diffuse large b‐cell lymphoma
26. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B‐cell lymphoma
27. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)
28. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma
29. Primary cardiac lymphoma mimicking infiltrative cardiomyopathy
30. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma
31. Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group
32. Aggressive natural killer cell leukemia: Therapeutic potential of l-asparaginase and allogeneic hematopoietic stem cell transplantation
33. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy
34. Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study
35. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission
36. Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases
37. 18F‐FDG uptake and its clinical relevance in primary gastric lymphoma
38. Depletion of l‐ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes
39. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS
40. Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia
41. TNFAIP3is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma
42. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease
43. Consideration of aggressive therapeutic strategies for primary testicular lymphoma
44. Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: Comparison with pulmonary and nodal marginal zone B cell lymphoma
45. Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1
46. Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases
47. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies
48. Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.